Bristol-Myers Squibb TYK2 inhibitor deucravacitinib enters review in the U.S. and Europe

Compilenewborn

On Monday, Bristol-Myers Squibb (BMS) announced that the U.

Deucravacitinib is the next-generation autoimmune drug of BMS.

But the problem is that TYK2 is a member of the JAK family, commonly known as JAK4

Samit Hirawat, chief medical officer of BMS, said in a recent interview that deucravacitinib has differentiated safety characteristics and does not have the downstream effects of JAK1/2/3, which is the target of existing JAK inhibitors

In order to win the U.

Data from 2 phase 3 clinical trials of plaque psoriasis announced earlier this year showed that BMS made the right choice

However, in October of this year, deucravacitinib also suffered a blow and failed in a phase 2 clinical trial for the treatment of ulcerative colitis (UC)

In addition to UC, BMS is also conducting another phase 2 clinical trial for the treatment of Crohn's disease (CD), which is another type of IBD

According to BMS estimates, all of these indications will be the basis for supporting deucravacitinib to reach a peak sales of $4 billion in 2029

BMS expects another asset with peak sales of more than $4 billion is the targeted heart drug mavacamten

Reference source: Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny